Hall Capital Management Co. Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 0.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 60,348 shares of the biopharmaceutical company’s stock after selling 415 shares during the quarter. Pfizer comprises approximately 1.9% of Hall Capital Management Co. Inc.’s holdings, making the stock its 20th largest position. Hall Capital Management Co. Inc.’s holdings in Pfizer were worth $2,027,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Northstar Group Inc. increased its position in Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 35 shares during the period. Peregrine Asset Advisers Inc. increased its position in Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares during the period. Northwest Quadrant Wealth Management LLC increased its position in Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares during the period. River Wealth Advisors LLC increased its position in Pfizer by 0.3% during the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 55 shares during the period. Finally, Meridian Wealth Management LLC increased its holdings in Pfizer by 0.5% in the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 57 shares during the period. Institutional investors and hedge funds own 69.89% of the company’s stock.

Several equities research analysts have issued reports on the stock. Deutsche Bank set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Friday. Berenberg Bank reissued a “hold” rating and issued a $36.00 price target (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. UBS set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Finally, Cowen set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. Pfizer has an average rating of “Buy” and a consensus price target of $38.77.

Pfizer Inc. (NYSE PFE) traded up $0.26 on Monday, hitting $36.00. 2,102,077 shares of the stock traded hands, compared to its average volume of 19,939,289. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $36.78. The company has a market cap of $213,035.67, a price-to-earnings ratio of 14.30, a price-to-earnings-growth ratio of 2.52 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the prior year, the firm earned $0.61 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. sell-side analysts predict that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.56%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s payout ratio is 79.01%.

In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/12/11/hall-capital-management-co-inc-has-2-03-million-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.